{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T18:32:46Z","timestamp":1763058766994,"version":"3.40.5"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Anlotinib is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor, and has been approved for the treatment of patients with advanced nonsmall cell lung cancer who had received at least 2 previous chemotherapy and epidermal growth factor receptor\/anaplastic lymphoma kinase targeted therapy regimens. Pneumothorax is a rare adverse reaction of this drug. Here, we present a case of pneumothorax following anlotinib treatment in a patient with lung cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 61-year-old Asian male long-term smoker was admitted to the hospital in November 2019 with sputum production and dyspnea.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The patient was diagnosed with right lung adenocarcinoma with mediastinal and rib metastases, combined with chronic obstructive pulmonary disease and pulmonary bullous disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient was treated with oral administration of anlotinib. The patient had a recurrent pneumothorax that improved after drug withdrawal and was free of recurrence. Therefore, pneumothorax caused by rupture of the pulmonary bullous due to anlotinib was considered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After discontinuing anlotinib, the patient has not developed pneumothorax to date.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Pneumothorax may occur when VEGF is inhibited, which can promote the proliferation and repair of alveolar wall substances, leading to alveolar rupture. With respect to pneumothorax, it is necessary to be aware of the risk of pulmonary bullous rupture during antitumor treatment with small-molecule tyrosine kinase drugs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029273","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T14:03:52Z","timestamp":1658498632000},"page":"e29273","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Pneumothorax in lung cancer following anlotinib treatment: A case report"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0418-6987","authenticated-orcid":false,"given":"Lei","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The First People's Hospital of Neijiang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.lungcan.2018.05.013","article-title":"Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small-cell lung cancer","volume":"122","author":"Si","year":"2018","journal-title":"Lung Cancer"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/1759-7714.12977","article-title":"Management of anlotinib-related adverse events in patients with advanced non-small-cell lung cancer: experiences in ALTER-0303","volume":"10","author":"Si","year":"2019","journal-title":"Thorac Cancer"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2045-3329-4-14","article-title":"Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series","volume":"4","author":"Verschoor","year":"2014","journal-title":"Clin Sarcoma Res"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/cncr.29961","article-title":"The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study","volume":"122","author":"Nakamura","year":"2016","journal-title":"Cancer"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1186\/s12885-016-2786-z","article-title":"Risk factors for pneumothorax in advanced and\/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis","volume":"16","author":"Nakano","year":"2016","journal-title":"BMC Cancer"},{"key":"R8-20250504","first-page":"5","article-title":"Rak p\u0142uca i przewlek\u0142a obturacyjna choroba p\u0142uc \u2013 narastaj\u0105cy problem kliniczny [Lung cancer and COPD \u2013 growing clinical problem]","volume":"43","author":"Tyl","year":"2017","journal-title":"Pol Merkur Lekarski"},{"key":"R9-20250504","first-page":"559","article-title":"Risk of gastrointestinal perfusion in cancer patients treated with bevacizumab: a meta-analysis","author":"Pan","year":"2009","journal-title":"Lancet"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:05:17Z","timestamp":1746331517000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":9,"journal-issue":{"issue":"29","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029273","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,7,22]]}}}